-
A New Type of Drug ApprovalAt the AACR Annual Meeting, researchers and regulators discuss what it means to tie approval of an immunotherapy to tumors' molecular characteristics, not to their tissues of origin.
by Kate Yandell
-
Artificial Intelligence Characterizes CancerAt the AACR Annual Meeting 2018, researchers at Google compared the speed and accuracy of human pathologists and computer algorithms in diagnosing and grading cancer.
by Kevin McLaughlin
-
Non–Small Cell Lung Cancer Takes Center StageA trio of clinical trials at the AACR Annual Meeting spotlight new avenues for non-small cell lung cancer treatment.
by Brad Jones
-
Cancer Researchers Offer Reasons for OptimismCancer researchers and patient advocates spoke about progress against cancer at a public education forum sponsored by the American Association for Cancer Research.
by Kevin McLaughlin
-
Pembrolizumab Shows Further Promise for MelanomaIn a phase III clinical trial, pembrolizumab yielded a 75.4 percent recurrence-free survival rate after 12 months among patients whose stage III melanoma tumors had been fully resected.
by Brad Jones
-
The Evolving Role of Patient AdvocacyAACR’s Scientist↔Survivor Program marks a milestone as patient advocates continue to shape research and policy.
by Marci A. Landsmann
-
An Advocate’s Guide to Attending Scientific MeetingsTwo graduates of the AACR Scientist↔Survivor Program share tips for getting the most out of large scientific conferences.
by Bob Riter and Carole Baas
-
Making Decisions About Breast SurgeryPatients who opt for breast reconstruction after mastectomy tend to overestimate how happy they will be with the results, while those who do not get reconstruction tend to underestimate their future satisfaction.
by Cici Zhang
-
A Better Way to Screen for Lynch Syndrome?Researchers say a next-generation sequencing test could improve screening in colorectal cancer patients for a hereditary syndrome that raises cancer risk. Some experts have concerns.
by Cheryl Platzman Weinstock
-
Making Sense of Cancer ProgressCancer Today editor Kevin McLaughlin contemplates what it means to report on cancer research advances when so many continue to die of the disease.
by Kevin McLaughlin
Immunotherapies, cancer vaccines and more from Cancer Today’s coverage of the AACR Annual Meeting 2025.
Redefining Cancer SurvivorshipAs people with advanced disease live longer, they face physical and mental health side effects. Patient advocates say research and care must focus on their unique needs.
by Thomas Celona
Family of Henrietta Lacks Works for ‘Health Intelligence’Alfred Lacks Carter Jr. and other family members honor the legacy of Henrietta Lacks by helping others better understand their health care.
by Kevin McLaughlin
Researchers Tackle Immune-related Adverse EffectsScientists present data on the risks of immune checkpoint inhibitors so more patients can tap into the treatment.
by Marci A. Landsmann
-
Inaugural AACR IO Conference Kicks Off With Celebration of Immune CheckpointsImmune checkpoint icons James Allison and Arlene Sharpe shared their journeys and a look ahead on the opening night of the inaugural AACR IO conference.
-
A New Resource Provides a Sanctuary for Black TNBC PatientsThe Black TNBC Sanctuary was created to help Black women with triple-negative breast cancer get answers about their diagnosis and care.
Dr. Humberto M. Guiot: Targeting Pancreatic Cancer in a Community-Based Clinical Trial
